HIV Developing Resistance to Key Drug

HIV is developing a resistance to key drug Tenofovir. A study looking at 2,000 HIV patients worldwide found that the virus was resistant in 60 percent of cases in several African countries. In Europe, that number was 20 percent. Lead author Ravi Gupta called the results, which were published in The Lancet Infectious Diseases journal, “extremely concerning.” Officials said improper administration of the drug may be causing the difference. Gupta said, “If the right levels of the drug are not taken, as in they are too low or not regularly maintained, the virus can overcome the drug and become resistant.”